Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 449  
ORIGINAL ARTICLE
Year : 2016  |  Volume : 15  |  Issue : 1  |  Page : 7-11

Nanotamoxifen delivery system: Toxicity assessment after oral administration and biodistribution study after intravenous delivery of radiolabeled nanotamoxifen


1 Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Pathology, All Institute of Medical Sciences, New Delhi, India
3 Department of Lab Medicine All Institute of Medical Sciences, New Delhi, India
4 Department of Molecular Cardiology, Dr. BR Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India
5 Department of Nuclear Medicine and PET, All Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Jaya Shukla
Department of Nuclear Medicine and PET, Post Graduate Institute of Medical Education and Research, Chandigarh - 160 012, Haryana and Punjab
India
Login to access the Email id


DOI: 10.4103/1450-1147.167594

PMID: 26912972

Rights and Permissions

Tamoxifen is the most prescribed anticancer oral drug for increasing overall survival and decreasing recurrence and the risk of contralateral disease. However, some side effects, such as endometrial and liver tumors, thromboembolic disorders, and drug resistance, are associated with long-term tamoxifen treatment. We assessed the hematologic and organ toxicity after oral administration of three different doses of nanotamoxifen formulations. We also performed biodistribution studies of Technetium-99m (99mTc)-nanotamoxifen after intravenous administration. The results demonstrated that nanotamoxifen was well-tolerated, with no adverse effect on biochemical parameters of blood and at the cellular level. Nitric oxide (NO) levels indicated no free radical formation. Oral nanotamoxifen is well-tolerated, with no hepatic or renal toxicity. Intravenous nanotamoxifen has potential to escape the liver, and is known for producing the harmful metabolite 4-hydroxytamoxifen (4OH-tamoxifen), which can cause uterine cancer.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1931    
    Printed54    
    Emailed0    
    PDF Downloaded167    
    Comments [Add]    

Recommend this journal